Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term outcomes of SUBLOCADE in adults with opioid use disorder
2023-505098-34-00Phase 4Completed
- Sponsor
- Indivior
- Start
- Apr 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 4, open-label, single-arm trial of buprenorphine in opioid use disorder (OUD), sponsored by Indivior. Primary endpoint: DSM-5 remission status while on SUBLOCADE. Started Apr 2024; status: completed.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on 2023-505098-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505098-34-00.